Alopecia

In this retrospective study, investigators highlight the effectiveness and safety of baricitinib and systemic corticosteroid addition for alopecia areata.

These findings highlight the potential for JAKi use in alopecia areata in terms of associated neuroimmune dysregulation and comorbidities.

Notable psychosocial and occupational burdens, as well as impairments to emotional well-being, were seen among caregivers of adolescents with alopecia.

In this analysis, investigators highlight the efficacy and safety of azathioprine as a monotherapy for those with recalcitrant and severe alopecia areata.

In this iteration of our Month in Review series, we highlight some of the most notable stories covered in April in the dermatology field.

This analysis was a single-center retrospective cohort study, with investigators highlighting an underrecognized alopecia pattern.

This announcement by Q32 Bio Inc. highlights the Fast Track designation by the FDA granted to bempikibart (ADX-914) for alopecia areata.

These data were the conclusion of a case series highlighting the experiences and responses of African American patients with alopecia areata who utilize JAK inhibitors.

These findings point to a need for evidence-based digital health information access to counter misinformation regarding androgenetic alopecia.

In this letter to the editor, investigators highlight the issues faced by patients with alopecia areata and the common barriers to JAK inhibitor access.

These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.

In new preference research, the average participant with AA was willing to trade approximately 5 years of life to avoid impacts associated with 50–100% scalp hair loss.

Healthier hair and scalp according to Hair & Scalp CARE questionnaire responses was linked to lower levels of perceived stress and good sleep health.

The findings may facilitate accurate diagnoses, which could help patients slow or stop permanent hair loss.

Our top 5 headlines spotlight FDA approvals for maralixibat and dupilumab, plus key trial results in diabetes, cardiovascular disease, and retinal vein occlusion.

This network meta-analysis compares the relative effectiveness and safety of different monotherapies for patients living with alopecia areata.

Side effects of baricitinib were well within safety parameters, indicating the drug’s viability as a alopecia treatment for adults.

This systematic review highlights current research on ruxolitinib’s off-label use in dermatology, specifically for conditions such as alopecia and psoriasis.

These data on 5α-reductase inhibitors highlight impacts on patients with benign prostatic hyperplasia or androgenic alopecia.

This analysis demonstrates the effectiveness of methotrexate application via microinfusion in frontal fibrosing alopecia.

These data highlight the potential impacts of baricitinib across significant hair-bearing areas involved in alopecia areata.

This retrospective, real-world analysis highlights several notable findings on JAK inhibitor use among patients with alopecia areata.

This episode of the SOCS podcast features an in-depth discussion between Crystal Aguh, MD, and John Harris, MD, PhD.

In this analysis, the investigators evaluated the temporal increase in hair shedding amounts following topical minoxidil utilization.

Caution may be needed when prescribing 5 mg of oral minoxidil to patients with alopecia and pericardial risk factors such as systemic lupus erythematosus.